Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex for Recovery After Laparoscopic Bariatric Surgery
NCT06678451Not yet recruiting
- Sponsor
- Shanxi Bethune Hospital
- Start
- Dec 2024
- Primary completion
- May 2025
- Modality
- Biodegradable Polymers, Small Molecules
01
Overview
Randomised, double-blind trial of Sugammadex in obesity (2 arms), sponsored by Shanxi Bethune Hospital. Primary endpoint: Postoperative muscle relaxation recovery at 30 minutes. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
Sugammadex
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06678451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06678451.